Author

Laurent Peyrin-Biroulet

OZANIMOD IS AN EFFECTIVE ORAL TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS REGARDLESS OF MODERATE OR SEVERE ENDOSCOPIC DISEASE ACTIVITY: A POST HOC ANALYSIS OF TRUE NORTH
OZANIMOD IS AN EFFECTIVE ORAL TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS REGARDLESS OF MODERATE OR SEVERE ENDOSCOPIC DISEASE ACTIVITY: A POST HOC ANALYSIS OF TRUE NORTH

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL

Laurent Peyrin-Biroulet  et al.

Combination therapies in 2020
Combination therapies in 2020

Laurent Peyrin-Biroulet

Breaking the ‘therapeutic ceiling’ in the management of Crohn’s disease: hype or hope? (Takeda Pharmaceuticals International AG)
Breaking the ‘therapeutic ceiling’ in the management of Crohn’s disease: hype or hope? (Takeda Pharmaceuticals International AG)

Laurent Peyrin-Biroulet  et al.

EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Laurent Peyrin-Biroulet  et al.

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Laurent Peyrin-Biroulet  et al.

Therapeutic end-points: What matters?
Therapeutic end-points: What matters?

Laurent Peyrin-Biroulet

THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM A GLOBAL UC PATIENT SURVEY
THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM A GLOBAL UC PATIENT SURVEY

Laurent Peyrin-Biroulet  et al.

Addressing diagnostic delay and differential diagnosis
Addressing diagnostic delay and differential diagnosis

Laurent Peyrin-Biroulet

Weighing up treatment options in UC: how do we interpret the evidence for JAK inhibition? (Pfizer)
Weighing up treatment options in UC: how do we interpret the evidence for JAK inhibition? (Pfizer)

Laurent Peyrin-Biroulet  et al.

ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS PREVIOUSLY EXPOSED TO ANTI–TUMOR NECROSIS FACTOR AGENT: THE RANDOMIZED, PHASE 3 HICKORY TRIAL
ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS PREVIOUSLY EXPOSED TO ANTI–TUMOR NECROSIS FACTOR AGENT: THE RANDOMIZED, PHASE 3 HICKORY TRIAL

Laurent Peyrin-Biroulet

ASSOCIATION BETWEEN EFFICACY AND LONG-TERM OUTCOMES: FOUR YEAR RESULTS FROM THE UNIFI STUDY OF USTEKINUMAB IN ULCERATIVE COLITIS
ASSOCIATION BETWEEN EFFICACY AND LONG-TERM OUTCOMES: FOUR YEAR RESULTS FROM THE UNIFI STUDY OF USTEKINUMAB IN ULCERATIVE COLITIS

Laurent Peyrin-Biroulet  et al.

CLINICAL AND ENDOSCOPIC OUTCOMES WITH USTEKINUMAB IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE LONG-TERM EXTENSION PERIOD OF THE STARDUST TRIAL
CLINICAL AND ENDOSCOPIC OUTCOMES WITH USTEKINUMAB IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE LONG-TERM EXTENSION PERIOD OF THE STARDUST TRIAL

Laurent Peyrin-Biroulet  et al.

From STRIDE 1 to STRIDE 2: Evidence for changes
From STRIDE 1 to STRIDE 2: Evidence for changes

Laurent Peyrin-Biroulet

EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Laurent Peyrin-Biroulet  et al.

A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Laurent Peyrin-Biroulet  et al.

PRA023 IMPROVED HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY IBDQ-32 IN A PHASE 2 TRIAL FROM PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
PRA023 IMPROVED HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY IBDQ-32 IN A PHASE 2 TRIAL FROM PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Laurent Peyrin-Biroulet  et al.

Bringing light into new treatment targets: the role of histology and molecular healing in UC (Eli Lilly and Company) (Complete Session)
Bringing light into new treatment targets: the role of histology and molecular healing in UC (Eli Lilly and Company) (Complete Session)

Laurent Peyrin-Biroulet  et al.

TREATMENT DISCONTINUATION DUE TO LACK OF EFFICACY DURING MAINTENANCE TREATMENT WITH INFLIXIMAB OR VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
TREATMENT DISCONTINUATION DUE TO LACK OF EFFICACY DURING MAINTENANCE TREATMENT WITH INFLIXIMAB OR VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Laurent Peyrin-Biroulet  et al.

Item 21 - 40 / 115
1
2
3 4 5 6